Aim
To compare four cardiovascular disease (CVD) risk models and to assess the prevalence of eligibility for lipid lowering therapy according to the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, European AIDS Clinical Society Guidelines (EACS), and European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS) guidelines for CVD prevention in HIV infected patients on antiretroviral therapy.

Methods
We performed a cross-sectional analysis of 254 consecutive HIV infected patients aged 40 to 79 years who received antiretroviral therapy for at least 12 months. The patients were examined at the HIV-treatment centers in Belgrade and Zagreb in the period February-April 2011. We compared the following four CVD risk models: the Framingham risk score (FRS), European Systematic Coronary Risk Evaluation Score (SCORE), the Data Collection on Adverse Effects of Anti-HIV Drugs study (DAD), and the Pooled Cohort Atherosclerotic CVD risk (ASCVD) equations.

Results
The prevalence of current smoking was 42.9%, hypertension 31.5%, and hypercholesterolemia (>6.2 mmol/L) 35.4%; 33.1% persons were overweight, 11.8% were obese, and 30.3% had metabolic syndrome. A high 5-year DAD CVD risk score (>5%) had substantial agreement with the elevated (≥7.5%) 10-year ASCVD risk equation score (kappa = 0.63). 21.3% persons were eligible for statin therapy according to EACS (95% confidence intervals [CI], 16.3% to 27.4%), 25.6% according to ESC/EAS (95% CI, 20.2% to 31.9%), and 37.9% according to ACC/AHA guidelines (95% CI, 31.6 to 44.6%).

Conclusion
In our sample, agreement between the high DAD CVD risk score and other CVD high risk scores was not very good. The ACC/AHA guidelines would recommend statins more often than ESC/EAS and EACS guidelines. Current recommendations on treatment of dyslipidemia should be applied with caution in the HIV infected population.
Observational studies found higher rates of myocardial infarction and cerebrovascular events in HIV infected than in uninfected persons (1-6). Hence, prevention of cardiovascular disease (CVD) in HIV infected patients should be an integral part of current clinical practice. In routine HIV clinical care in developed countries it is recommended to calculate the CVD risk using prediction models (7-9). Preventable and modifiable predisposing factors for CVD should be identified, and lifestyle and pharmacological interventions should be undertaken.

CVD prevention in HIV-infected persons is mainly based on recommendations for the HIV uninfected population. The American College of Cardiology/American Heart Association (ACC/AHA) published the 2013 Guideline on the Assessment of Cardiovascular Risk (10) and the European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) published one of the major European guidelines (11). The European AIDS Clinical Society (EACS) addresses many complications of HIV disease, including recommendations for lipid lowering therapy (7). All guidelines use different models for assessing cardiovascular risk. EACS recommends the Framingham Risk Scoring (FRS), while ESC/EAS recommends the European Systematic Coronary Risk Evaluation score (SCORE). The FRS has been widely used for estimation of coronary heart disease (angina, myocardial infarction, and coronary death), hard coronary events (myocardial infarction and coronary deaths), stroke, and global CVD (including CVD deaths, coronary disease, transient ischemic attack, and stroke) (12). SCORE estimates the 10-year risk of a first fatal atherosclerotic event (eg, myocardial infarction, stroke, aortic aneurysm), and calibrated versions exist to adjust for different death rates in European countries (13). These estimates have an important role in identifying high risk patients and in recommending lipid lowering therapy (7,11,14). ACC/AHA recommends the Pooled Cohort Equations for atherosclerotic cardiovascular disease (ASCVD) risk to evaluate the need for treatment of blood cholesterol levels in the non-HIV infected population (10).

CVD risk estimation formulas are primarily intended to assist physicians in identifying high risk healthy persons older than 40 years with no signs of clinical atherosclerotic disease (7,10,11,14). Patients with diabetes are generally recommended more intensive interventions and considered at a higher risk for CVD (11,14). Cardiovascular risk models designed for the HIV infected population have also been developed, the most widely known is the Data Collection on Adverse Effects of Anti-HIV Drugs Study (DAD) risk equation, which also includes HIV-specific variables such as duration of indinavir or lopinavir use and current use of indinavir, lopinavir, or abacavir (15). However, the follow-up in the DAD Study is still relatively short and the DAD risk equation has yet not been formally recommended for CVD risk assessment in routine clinical care for HIV-infected persons.

Southeastern European countries such as Bulgaria, Croatia, Hungary, Romania, and Serbia have high rates of age-standardized mortality from cardiovascular disease, (ie, ischemic heart disease and cerebrovascular disease) (16,17). The aim of our study was to analyze the agreement of the high DAD CVD score with other CVD scores (CVD-FRS, SCORE, ASCVD) developed for the non-HIV infected population in HIV infected patients receiving antiretroviral therapy (ART) in Croatia and Serbia. We also examined the prevalence of eligibility for lipid lowering therapy according to the 2013 ACC/AHA guidelines, EACS, and European ESC/EAS guidelines for cardiovascular disease prevention.

METHODS

Settings

The study was conducted at the University Hospital for Infectious Diseases, Zagreb, Croatia and the HIV/AIDS Unit, Institute for Infectious and Tropical Diseases, School of Medicine, University of Belgrade, Belgrade, Serbia, in the period February-April 2011. Both Croatia and Serbia have a low-level HIV epidemic (18,19). Croatia has a centralized system of care for HIV and all patients are treated in one center. The number of patients treated per one calendar year in the period 2011-2013 ranged from 650 to 780. In Serbia, there are currently four HIV treatment centers. The Institute for Infectious and Tropical Diseases, School of Medicine, University of Belgrade was established in 1985 and is by far the largest one. In the period 2011-2013, it treated 1000 to 1200 people living with HIV per year. In Croatia and Serbia health care insurance is universal and free of charge, however, the number of approved antiretrovirals is limited, and older, less lipid friendly antiretrovirals, are still being used (20,21).

Study population

We collected data on risk factors for CVD for all consecutive HIV infected patients seen at a scheduled visit for routine follow-up in the two centers. We included persons 40 to 79 years old in whom lipid measurements
were done and who had at least 12 months of antiretroviral therapy (ART). We excluded pregnant women and patients with acute illness or exacerbation of a chronic illness at the time of evaluation. A total of 355 persons were seen at the treatment center in Zagreb, 132 of whom met our eligibility criteria. At the treatment center in Belgrade 712 persons were examined, 122 of whom met our eligibility criteria.

A standardized data collection form was developed which included information on sociodemographic characteristics, HIV disease characteristics (current CD4 cell count, HIV-1 viral load, past and current history of ART), known risk factors for CVD (family history of premature CVD, smoking, hypertension, age, sex), lipids (total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride), blood glucose measurements, and hepatitis B and C coinfection. The study was approved by the Ethics Committee of the University Hospital for Infectious Diseases, Zagreb, Croatia and the Clinical Center of Serbia Ethics Committee.

Definitions

CVD was considered present if a history of any of the following conditions existed on inclusion into the study: myocardial infarction, stable/unstable angina, invasive coronary artery procedure, carotid artery disease (symptomatic [eg, transient ischemic attack or stroke] or >50 percent stenosis on angiography or ultrasound), stroke, peripheral artery disease, abdominal aortic aneurysm or other forms of clinical atherosclerotic disease (eg, renal artery disease). Family history of premature cardiovascular events was considered present if the event occurred in a male first-degree relative <55 years or female first-degree relative <65 years. Diabetes mellitus was defined if at least two fasting plasma glucose levels were ≥7.0 mmol/L, casual plasma glucose >11.1 mmol/L, or if patient had a history of diabetes treatment.

Arterial hypertension was defined as systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 mm Hg (>135/85 mm Hg in diabetic patients) or taking antihypertensive drugs. Blood pressure was measured by the attending nurse using mercury sphygmomanometers. The patient was in a seated position; his or her arm was supported and flexed at the level of the heart. The stethoscope’s bell was lightly pressed over the brachial artery just below the cuff’s edge. The first knocking sound (Korotkoff) indicated the patient’s systolic pressure and the disappearance of the knocking sound indicated diastolic pressure.

Dyslipidemia was considered present if total cholesterol >6.2 mmol/L, HDL-cholesterol <1.03, or fasting triglycerides >2.26 mmol/L. We used the modified updated National Cholesterol Education Program criteria for the definition of metabolic syndrome: triglycerides of at least 1.7 mmol/L, HDL of 1.0 mmol/L or less in men and of 1.3 mmol/L or less in women, hypertension (systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg), or use of antihypertensive medications and a glucose level at least 5.6 mmol/L or the diagnosis of diabetes. Body mass index was used as a surrogate for waist circumference.

Ten-year risk for CVD was calculated using the Framingham equation (23) available as a web-based tool (http://hivpv.org/Home/Tools). The score was categorized as follows: <10% – low risk; 10%-20% – moderate risk; ≥20% – high risk. We also calculated the SCORE, which evaluates the 10-year risk of the first fatal atherosclerotic event (for example, myocardial infarction, stroke, and aortic aneurysm). We used the SCORE equation for high-risk countries, since the guidelines consider Croatia and Serbia as high-risk countries (13). Persons were considered at low risk if the score was <1%, at moderate risk if score was 1%-5%, and at high risk if the score was ≥5%. We applied the DAD risk equation exactly as published (15); a 5-year CVD risk >5% was considered high. The Pooled Cohort equation for ASCVD was calculated according to instructions in the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol (10). The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL-cholesterol, systolic blood pressure, antihypertensive drug use, diabetes, and smoking status. The score estimates a 10-year risk for ASCVD for men and women 40 to 79 years of age. The analysis of agreement of high risk scores derived from the different CVD risk models included 213 individuals without known CVD events, without diabetes, and with total serum cholesterol ≤8 mmol/L and LDL-cholesterol ≤4.9 mmol/L.

Eligibility for lipid lowering therapy was assessed in 211 persons not receiving lipid lowering agents. We used three different guidelines; EACS, ESC/EAS, and the ACC/AHA guidelines. The current EACS guidelines use the CVD-FRS for defining eligibility for lipid lowering therapy. Therapy is recommended in patients with established CVD, diabetes, or 10-year CVD-FRS≥20% (7). We considered persons eligible for lipid lowering therapy according to the ESC/EAS guidelines if they already had a CVD event, diabetes,
or total cholesterol ≥8 mmol/L (11). Individuals were also considered to be eligible if the calculated SCORE value was between 5 and 10% and the LDL-cholesterol was ≥2.5 mmol/L or the SCORE value was ≥10% and LDL-cholesterol was ≥1.8 mmol/L (11). Individuals in whom therapy is "considered" by the ESC/EAS guidelines were classified in the "not recommended" group. According to the 2013 ACC/AHA guidelines, individuals with the following conditions are eligible for lipid-lowering therapy: 1) presence of CVD, 2) primary elevations of LDL-C≥4.9 mmol/L, 3) diabetes with LDL-C 1.8 to 4.9 mmol/L, and 4) an LDL-C level 1.8 to 4.9 mmol/L with an estimated 10-year ASCVD risk of ≥7.5% and without established CVD or diabetes (10).

Statistical analysis

Continuous variables were presented as medians and the first to third quartile (Q1-Q3) range. Categorical variables were presented as frequencies with percentages. The Agresti-Coull method was used for calculating 95% confidence intervals (CI) for proportions. We evaluated agreement between different high cardiovascular risk scores in a subset of 213 non-diabetic persons without a history of cardiovascular events and total cholesterol ≤8 mmol/L and LDL-cholesterol ≤4.9 mmol/L. This agreement was evaluated using the following cut-offs: 10-year CVD-FRS≥20%, 10-year SCORE≥5%, 10-year ASCVD risk ≥7.5%, and DAD CVD score >5%. Agreement between these categorized cardiovascular risk scores was assessed by observed agreement, agreement for higher and lower scores, and the Cohen’s kappa (κ) statistics. The delta method suggested by Mackinnon (24) was used for calculating the 95% CI for agreement for higher and lower scores. Patients who already used statins were not evaluated for the eligibility for lipid lowering therapy (n=43). Agreement for the eligibility for lipid lowering therapy by the EACS, ESC/EAS, and ACC/AHA guidelines was also assessed by κ statistics. The level of agreement was considered poor if κ ≤ 0.20, fair if 0.21 ≤ κ ≤ 0.40, moderate if 0.41 ≤ κ ≤ 0.60, substantial if 0.61 ≤ κ ≤ 0.80, and very good if κ > 0.80. All statistical analyses were done using SAS software, version 9.3. (SAS Institute, Cary, NC, USA).

RESULTS

A total of 254 patients (122 from Serbia and 132 from Croatia) were included in the study. (Table 1). Of 254 persons, 193 (76%) were men. Of 61 women, 43 (70.5%) were from Belgrade. Women were younger than men (median 47 vs 50 years). All study participants were Caucasians.

The prevalence of high CVD scores or risk equivalents was noticeable and it ranged from 27.2% (69 of 254) for the CVD-FRS to 51.6% for the DAD score (131 of 254) (Table 2, Figure 1). Of note, 58.3% of persons had a CVD-FRS≥10%, 71.5% of persons had a SCORE>1%, and 98.4% had a DAD score >1%. Current use of abacavir and the use of protease inhibitors contributed significantly to the high DAD CVD risk score (Table 2). Of 254 persons, 84 (33.1%) were overweight (body mass index, 25-29.9) and 30 (11.8%) were obese. A clinical CVD event was present in 8 persons (myocardial infarction, 6; stroke, 1; and coronary angiography with stenting, 1) and diabetes in 10.

We evaluated agreement between the high 5-year CVD DAD score and the 10-year CVD-FRS, 10-year CVD SCORE, and 10-year ASCVD risk score in 213 non-diabetic persons from Croatia and Serbia.*

**TABLE 1.** Major HIV-disease characteristics of 254 HIV infected persons from Croatia and Serbia*

| Characteristics                          | Total (N = 254) | Serbia (N = 122) | Croatia (N = 132) |
|-----------------------------------------|----------------|-----------------|-------------------|
| Mode of transmission                    |                |                 |                   |
| Men who have sex with men               | 75 (29.5)      | 11 (9.0)        | 64 (48.5)         |
| Sex between men and women               | 94 (37.0)      | 41 (33.6)       | 53 (40.2)         |
| Intravenous drug use                     | 22 (8.7)       | 15 (12.3)       | 7 (5.3)           |
| Other/unknown                           | 63 (24.8)      | 55 (45.1)       | 8 (6.1)           |
| Current CD4 cell count, mm³              | 484 (311-661)  | 452 (274-674)   | 507.5 (365-658)   |
| Current viral load*                     |                |                 |                   |
| HIV-1 RNA<200 copies/mL                 | 242 (97.2)     | 115 (98.3)      | 127 (96.2)        |
| HIV-1 RNA≥200 copies/mL                 | 7 (2.8)        | 2 (1.7)         | 5 (3.8)           |
| Current use of abacavir                 | 79 (64.8)      | 138 (54.3)      | 59 (44.4)         |
| Current use of lopinavir/ritonavir      | 94 (37.0)      | 47 (38.5)       | 47 (35.6)         |
| Has antibody to hepatitis C virus       | 30 (11.8)      | 16 (13.1)       | 14 (10.6)         |
| Hepatitis B surface antigen positive    | 19 (7.5)       | 12 (9.8)        | 7 (5.3)           |

*Values are n (%) or medians (Q1-Q3).

15 patients from Serbia had no viral load measurement.
sons without a history of cardiovascular events and serum cholesterol ≤8 mmol/L and serum LDL-cholesterol <4.9 mmol/L (Table 3). The agreement between the 5-year CVD DAD score and 10-year ASCVD risk score was better (κ = 0.63) than between the DAD score and CVD-FRS or SCORE algorithms (κ = 0.47 for both) (Table 3).

**TABLE 2.** Prevalence of major cardiovascular risk factors and antiretroviral therapy by different high cardiovascular disease risk scores**

| Overall (n = 254) | FRS≥20 (n = 69) | SCORE≥5 (n = 80) | ASCVD≥7.5 (n = 110) | DAD≥5 (n = 131) |
|-------------------|-----------------|------------------|---------------------|------------------|
| Age, years          | 49 (44-55)     | 57 (52-64)     | 57 (52-64)         | 55 (49-61)       | 54 (49-60)       |
| Sex, male           | 193 (76.0)    | 65 (94.2)      | 72 (90.0)          | 95 (86.4)        | 114 (87.0)       |
| Hypertension >140/90 or >135/85 mm Hg if diabetic | 80 (31.5) | 38 (55.1) | 38 (47.5) | 49 (44.5) | 54 (41.2) |
| Diabetes mellitus   | 10 (3.9)       | 10 (14.5)      | 10 (12.5)          | 10 (9.1)         | 10 (7.6)         |
| Current smoker      | 109 (42.9)     | 40 (58.0)      | 39 (48.8)          | 59 (53.6)        | 75 (57.3)        |
| Ex-smoker           | 78 (30.7)      | 13 (18.8)      | 19 (23.8)          | 24 (21.8)        | 35 (26.7)        |
| Cholesterol >6.2 mmol/L | 90 (35.4) | 29 (42.0) | 41 (51.3) | 55 (50.0) | 60 (45.8) |
| HDL-C<1.03 mmol/L for men and <1.3 women | 63 (24.8) | 15 (21.7) | 11 (13.8) | 27 (24.5) | 29 (22.1) |
| Triglycerides >2.26 mmol/L | 96 (37.8) | 34 (49.3) | 33 (41.3) | 61 (46.4) | 61 (46.6) |
| Dyslipidemia*       | 164 (64.6)     | 48 (69.6)      | 55 (68.8)          | 82 (74.6)        | 84 (71.8)        |
| Family history of cardiovascular disease | 20 (7.9) | 3 (4.3) | 3 (3.8) | 5 (4.5) | 7 (5.3) |
| Metabolic syndrome  | 77 (30.3)      | 30 (43.5)      | 29 (36.3)          | 41 (37.3)        | 47 (35.9)        |
| Body mass index (kg/m²) | 24.5 (22.3-27.3) | 25.1 (23.5-27.8) | 25.1 (23.5-27.8) | 25.1 (22.9-28) | 24.6 (22.8-27.6) |
| Current use of protease inhibitors | 145 (57.1) | 36 (52.2) | 42 (52.2) | 64 (58.2) | 89 (67.9) |
| Current use of abacavir | 138 (54.3) | 43 (62.3) | 50 (62.5) | 68 (61.8) | 91 (69.5) |
| Duration of protease inhibitor use, years | 2 (0-6) | 3 (1.5-6) | 3 (1.5-6) | 2.5 (0.9-6) | 4 (1.1-6) |
| Duration of antiretroviral therapy, years | 6 (3.5-10.4) | 6 (4-10.1) | 6 (4-10.1) | 6 (3.6-10.6) | 6.5 (4-11.1) |
| Current use of lipid lowering agents | 43 (16.9) | 24 (34.8) | 24 (30.0) | 30 (27.3) | 33 (25.2) |
| Current use of antihypertensive medications | 49 (19.3) | 24 (34.8) | 22 (27.5) | 31 (28.2) | 35 (26.7) |

**TABLE 3.** Agreement between the 5-year DAD high CVD score and other high cardiovascular disease risk scores in 213 individuals between 40 to 79 years of age**

| Cardiovascular risk scores | 5-year DAD CVD score | Observed agreement | Agreement for higher scores | Agreement for lower scores | Kappa |
|---------------------------|----------------------|--------------------|-----------------------------|---------------------------|-------|
| 10-year FRS               | ≤5%                  | 0.75 (0.68-0.80)   | 0.63 (0.53-0.72)            | 0.81 (0.76-0.86)          | 0.47 (0.36-0.57) |
|                          | ≥20%                 | 2                  | 45                          |                           |       |
| 10-year SCORE            | ≤5%                  | 0.75 (0.68-0.80)   | 0.63 (0.53-0.72)            | 0.81 (0.76-0.86)          | 0.47 (0.36-0.57) |
|                          | ≥5%                  | 2                  | 45                          |                           |       |
| 10-year ASCVD            | ≤7.5%                | 0.82 (0.76-0.87)   | 0.77 (0.70-0.84)            | 0.85 (0.81-0.90)          | 0.63 (0.53-0.73) |
|                          | ≥7.5%                | 6                  | 65                          |                           |       |

*CVD – cardiovascular disease; FRS – Framingham Risk Score; ASCVD – atherosclerotic cardiovascular disease; SCORE – European System for Cardiac Operative Risk Evaluation.
†Values are n (%) or medians (Q1-Q3).
‡Also included patients with diabetes and clinical events.
§Also included patients with diabetes, clinical events and serum cholesterol >8 mmol/L.
¶All patients in the four major statin benefit groups were considered to have an elevated CVD risk.
*FRS – 10-year Framingham Risk Score; SCORE – 10-year European Systematic Coronary Risk Evaluation score; DAD – 5-year Data Collection on Adverse Effects of Anti-HIV Drugs Study score; ASCVD – 10-year Atherosclerotic Cardiovascular Disease Risk Equation. HDL-C – high-density cholesterol.
EACS guidelines would recommend lipid lowering therapy to 21.3% of persons (95% CI, 16.3% to 27.4%; n = 211); ESC/EAS guidelines to 25.6% (95% CI, 20.2% to 31.9%; n = 211); and ACC/AHA guidelines to 37.9% (95% CI, 31.6% to 44.6%; n = 211) (Figure 1). The use of ACC/AHA guidelines would increase the number of persons eligible for lipid lowering therapy by 77.8% (95% CI, 63.6%-87.6%) compared to the EACS guidelines that use the CVD-FRS score. The agreement between the guidelines in terms of indication for lipid lowering therapy was $\kappa = 0.61$, 95% CI, 0.51-0.72 (ACC/AHA vs EACS); $\kappa = 0.71$, 95% CI, 0.61-0.81 (ACC/AHA vs ESC/EAS); and $\kappa = 0.71$, 95% CI, 0.60-0.82 (EACS vs ESC/EAS). The use of abacavir in persons with high CVD risks was quite frequent (~60 to 70%) and the use of lopinavir/ritonavir was ~30% (Table 2).

**DISCUSSION**

We found a relatively high number of patients who needed interventions to reduce their cardiovascular disease risks. About one fifth to more than one third of patients, depending on the risk equation used, needed intensive lifestyle modifications (cessation of smoking, diet, or weight loss) and lipid lowering therapy. The agreement between the high DAD CVD scores and the elevated ASCVD scores was substantial (ĸ = 0.63), however, the agreement between high DAD and high CVD-FRS, and the high DAD with high SCORE algorithm was only moderate (ĸ = 0.47). Hence, none of the agreements were very good (ĸ>0.80). Agreement for lower CVD scores was better than for higher scores (Table 3).

Although high CVD scores are used to make clinical decisions about initiating statin therapy, concordances of those high score categories derived from different algorithms have not, to our knowledge, been reported in the HIV infected population. De Socio et al reported data on cardiovascular risk profiles using different risk algorithms in 2007 (25) and 2008 (26). They found more men in the high Framingham coronary heart disease risk strata (>20%) than in the high SCORE algorithm group (>5%) (26). However, it is difficult to compare different studies because they include different populations and use different risk algorithms. For example, in the study by De Socio et al the mean age was 43 years and the mean SCORE percentage was 1.1. In our study, the mean age was 50.3 years and the mean SCORE percentage was 3.3. Also, the study by De Socio et al had been done before the DAD algorithm was developed.

CVD prediction algorithms have been developed with the purpose of identifying persons without known CVD who are at high risk of a cardiovascular event. They...
aim to aid physicians to decide when and how to use lipid lowering drugs. However, there is currently no consensus on which CVD risk algorithm should be used in the HIV-infected population. The EACS guidelines recommend statin therapy, in addition to lifestyle modifications, when the 10-years CVD-FRS is ≥20% (7). However, it has been reported that the FRS underestimates the occurrence of stroke (27) and myocardial infarction (28) in HIV infected patients. For the treatment of high blood cholesterol in the non-HIV infected population the use of the ASCVD algorithm has been recently suggested (10).

In our population of HIV infected patients without previous use of lipid lowering medications, we found that the recent ACC/AHA guideline would recommend statin therapy to 38% of persons. The application of the 2013 ACC/AHA guidelines that use the ASCVD score compared to the EACS guidelines that use the CVD-FRS would increase the number of eligible patients for lipid lowering therapy by 78%. The new cholesterol guidelines have also been recently compared to other guidelines in the non-HIV infected population (29). An analysis of 4209 individuals not receiving statins in the prospective Rotterdam cohort aged ≥55 years found that the new cholesterol guidelines would have recommended statins to 96% of men and 66% of women (29). Of note, 66.1% of men and 39.1% of women were included in the “treatment recommended” category by the ESC/EAS guidelines (29). In a recent study, Zanni et al compared the 2013 ACC/AHA guidelines with the 2004 Adult treatment Panel III Cholesterol guidelines in HIV infected patients with or without subclinical high risk coronary plaque (30). Similarly to our findings, the 2013 ACC/AHA cholesterol guidelines recommended statin therapy to a higher percentage of patients than 2004 guidelines (30).

The prevalence of cardiovascular risk factors in our sample of HIV infected patients from Croatia and Serbia was high: hypertension (31.5%), smoking (41.9%), past smoking (30.7%), dyslipidemia (64.6%), and overweight or obesity (44.9%). The prevalence of hypertension and dyslipidemia was higher or similar to recent studies from the USA (31), Switzerland (32,33), Italy (34), and Germany (35).

The increased risk of CVD among HIV infected people is associated with traditional factors such as age, male sex, hypertension, smoking, diabetes mellitus, pre-existing CVD, and hypercholesterolemia as in the general population (36). However, HIV infection itself is a CVD risk factor for subclinical atherosclerosis and clinical cardiovascular events (37-40). A low CD4+ cell count was found to be a risk factor for cardiovascular disease events (41,42). Certain drugs used for HIV treatment, eg, lopinavir/ritonavir, indinavir/ritonavir, amprenavir, and fosamprenavir have also been associated with an increased risk for myocardial infarction (43,44). There is a considerable controversy about the association of abacavir with CVD (44,45), and guidelines caution about abacavir use in patients with a high CVD risks (7). In our study, about 60% of patients with a high CVD risk were using abacavir. Given the unclear relationship between abacavir and CVD events (44,45), it seems prudent to avoid using abacavir in patients with high cardiovascular risk if other alternatives exist. However, in Croatia and Serbia abacavir is frequently used due to the unavailability of tenofovir in Serbia and higher cost of tenofovir-based formulations compared to abacavir formulations in Croatia.

Our study has several limitations. Due to cross-sectional design, there is a lack of data on the changes in CVD risk over time. The analysis included only patients between 40 and 79 years old, so the frequency of CVD risks might be higher than in the studies that included younger age groups. However, the age range we used is the age range in which different CVD risk equations have been primarily developed and validated. Different CVD scores can also be compared as interval variables with graphs such as the Bland-Altman graph (46). However, as interventions to reduce CVD risks are usually made by some cutoffs we decided to compare CVD risk models by the cutoff at which more intensive interventions are recommended. We were also unable to make a more detailed analysis of whether the targets for lipids or blood pressure were reached in patients using lipid lowering or blood pressure lowering therapy. Our study sample was not large and included only Caucasian individuals. Finally, our point prevalences of different cardiovascular risk factors should be interpreted with caution because of the convenience sampling method used.

Our data suggest that clinicians have to make decisions on lipid lowering therapy using inconsistent recommendations. Until more data with clinical outcomes becomes available, physicians need to decide which of the different available algorithms is best for predicting CVD events in their patients. We would prefer to use an algorithm and recommendations specifically developed for the HIV population. It also has to be remembered that the interpretation of a particular CVD risk algorithm should always include careful clinical assessment and judgment.
Acknowledgment Parts of this study were presented at the 13th European AIDS Conference/EACS, Belgrade, Serbia, October 2011 PE 9.5/2. The study was also presented as a poster at the 11th International Congress on Drug Therapy in HIV Infection, 2–6 November 2014, Glasgow, United Kingdom.

Funding The work was supported by grant No 175024 from the Ministry of Education and Science of the Republic of Serbia and by grant No 108-1080116-0098 from the Croatian Ministry of Science, Education and Sports.

Ethical approval received from the Ethics Committee of the University Hospital for Infectious Diseases, Zagreb, Croatia and the Clinical Center of Serbia Ethics Committee.

Declaration of authorship Conceived and designed the study: JB, GD, KV, DL, DJ. Contributed to data analysis: JB, GD, KV, JK, MPM, DL, DJ. Analyzed the data: JB, GD. Contributed to analysis tools: JB, DL, KV, JK, MPM, DL. Wrote the paper: JB, GD, MPM, DJ. All authors read and approved the final manuscript.

Competing interests All authors have completed the Unified Competing Interest form: at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29-35. Medline:18566319 doi:10.1161/CIRCULATIONAHA.107.189624
2 Group DADS, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35. Medline:17460226 doi:10.1056/NEJMoa062744
3 Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis. 2012;205 Suppl 3:S355-61. Medline:22577208 doi:10.1093/infdis/jis195
4 Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy EF, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-22. Medline:23459863 doi:10.1001/jamainternmed.2013.3728
5 Rasmussen LD, Ensgig FN, Christensen H, Gerstoft J, Kronborg G, Pedersen C, et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS. 2011;25:1637-46. Medline:21646903 doi:10.1097/QAD.0b013e3283493fb0
6 Chow FC, Regan S, Geske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60:351-8. Medline:22580566 doi:10.1097/QAI.b013e31825c7f24
7 European AIDS Clinical Society. EACS European Guidelines for treatment of HIV infected adults in Europe. Available from: http://www.eacsociety.org/Guidelines.aspx. Accessed: January 29, 2015.
8 Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27. Medline:12942391 doi:10.1086/378131
9 Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-81. Medline:19640227 doi:10.1086/605292
10 Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45. Medline:24222016 doi:10.1161/doi.10000437738.63853.7a
11 European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818. Medline:21712404
12 D’Agostino RB Sr. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis. 2012;205 Suppl 3:S355-61. Medline:22577209 doi:10.1093/infdis/jis195
13 Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. Medline:12788299 doi:10.1056/ISMEJ.2003.24.9871003
14 Expert Panel on Detection, E. Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. Medline:11368702 doi:10.1001/jama.285.19.2486
15 Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491-501. Medline:20543702 doi:10.1097/HJPER.0b013e32836a3650
16 Muller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008;29:1316-26. Medline:18256043 doi:10.1093/eurheartj/ehm604
17 Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health
DISEASE-RELATED CHANGES IN BLOOD VESSELS

Anderson KM, Odell PM, Wilson PW, Kannel WB. The emerging and re-emerging human immunodeficiency virus epidemics in Europe. Clin Microbiol Infect. 2013;19:917-29. Medline:24205884 doi:10.1111/1469-0691.12133

Turchinov D, Stanley C, Canchola JA, Rutherford GW, Novotny TE, Begovac J. Dyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy. Coll Antropol. 2009;33:423-30. Medline:19662759

Perovic Mihanovic M, Haque NS, Rutherford GW, Zekanis, Begovac J. Circumference and body mass index in HIV infection. HIV Med. 2011;12:124-5. Medline:21446941 doi:10.1016/j.hivmed.2010.00852.x

Mateen FJ, Post WS, Sacktor N, Abraham AG, Becker JT, Smith BR, et al. Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men. Neurology. 2013;81:2094-102. Medline:24212385 doi:10.1212/01.wnl.0000437296.97946.73

De Socio GV, Parruti G, Quirino T, Schillaci G, Adriani B, et al. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect. 2008;57:33-40. Medline:18436307 doi:10.1016/j.jinf.2008.03.007

Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D’Arminio Monforte A, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7:218-30. Medline:16630304 doi:10.1111/j.1468-1293.2006.00362.x

Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyerberg EW, et al. Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. JAMA. 2014;311:1416-23. Medline:24681960

Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III Cholesterol Guidelines Applied to HIV-infected Patients With/Without Subclinical High-risk Coronary Plaque. AIDS. 2014;28:2061-70. Medline:25265074 doi:10.1097/QAD.0000000000000360

Krauskopf K, Van Natta ML, Danis RP, Gangaputra S, Ackatz L, Addessi A, et al. Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy. J Int Assoc Provid AIDS Care. 2013;12:325-33. Medline:23764503 doi:10.1177/1726597413491432

Glass TR, Ungsederpand C, Wolbeers M, Weber R, Vernazza PL, Rickenbach M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7:400-10. Medline:16903986 doi:10.1111/j.1468-1293.2006.00400.x

Nuesch R, Wang Q, Elii L, Bernasconi E, Weber R, Cavassini M, et al. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr. 2013;62:396-404. Medline:23288033 doi:10.1097/QAI.0b013e3182847cd0

De Socio GV, Ricci E, Maggi P, Parruti G, Pucci G, Di Biagio A, et al. Prevalence, Awareness, Treatment, and Control Rate of Hypertension in HIV-infected Patients: The HIV-HY Study. Am J Hypertens. 2014;27:222-8. Medline:24077828 doi:10.1093/ajh/hpt182

Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012;19:267-74. Medline:21450595 doi:10.1177/2047487311398431

Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35:1373-81. Medline:24408888 doi:10.1093/eurheartj/ehu107

Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-12. Medline:17456578 doi:10.1210/jc.2006-2190

Currier JS, Taylor A, Boyd F, DeZii CM, Kawabata H, Burton CL, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-12. Medline:12869840 doi:10.1097/01.qad.0000096313.09504.6f

Viskovic K, Rutherford GW, Sudario G, Stemberger L, Brnic Z, Begovac J. Ultrasound measurements of carotid intima-media thickness and plaque in HIV-infected patients on the
Mediterranean diet. Croat Med J. 2013;54:330-8. Medline:23986273 doi:10.3325/cmj.2013.54.330

40 Guaraldi G, Zona S, Orlando G, Carli F, Ligabue G, Fiocchi F, et al. Human immunodeficiency virus infection is associated with accelerated atherosclerosis. J Antimicrob Chemother. 2011;66:1857-60. Medline:21653601 doi:10.1093/jac/dkr206

41 Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435-47. Medline:20597691 doi:10.1086/655144

42 Silverberg MJ, Leyden WA, Xu L, Horberg MA, Chao CR, Towner WJ, et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014;65:160-6. Medline:24442222 doi:10.1097/QAI.0000000000000009

43 Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228-30. Medline:20400883 doi:10.1097/QAD.0b013e3283391927

44 Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-30. Medline:20039804 doi:10.1086/649897

45 Ding X, Andracca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441-7. Medline:22932321 doi:10.1097/QAI.0b013e31826f993c

46 Edwards-Jackson N, Kerr S, Tieu H, Ananworanich J, Hammer S, Ruxrungtham K, et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med. 2011;12:510-5. Medline:21375686 doi:10.1111/j.1468-1299.2011.00916.x